I'm trying to come up with worst case figures so we have something to go on. Very rough but here goes.
Sale price = $60/course double Bio A within complementary medicine pricing(m12??). At some point we have to believe(or not)that it may be very good for alcohol and liver treaments so if it is I assume 1mill courses at that price is achievable? Nett after tax(35%)= $39.0m; nett after costs(20%)=$31.0m rounded. Fully diluted(250m) = approx $0.125 per share nett profit x PE 4 = $0.50. Does anyone think as a worst case these figures stack up? Just trying to get some positives from very strong negative posting.
Alby.
- Forums
- ASX - By Stock
- SLA
- interesting reaserch on solagran
interesting reaserch on solagran, page-22
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online